The biopharmaceutical industry in California is a dynamic sector focused on discovering, developing, and delivering innovative therapies. Companies range from startups to well-established corporations, targeting diseases through advanced biological techniques and personalized medicine. Key areas include immunotherapy, cancer treatment, and rare genetic disorders. The industry is expected to grow steadily as the demand for effective therapies rises, propelled by technological advancements and collaboration with research institutions. Notably, California is home to many of the world’s leading biotech firms, making it a hotspot for pharmaceutical innovation and investment opportunities.

This list features 22 prominent biopharmaceutical companies based in California, showcasing a split between large corporations and nimble startups. Founded between 1992 and 2023, these companies focus on various specializations, including cancer treatment, food allergies, and immunotherapy. Most firms employ between 11 and 1,000 people, demonstrating the sector's broad appeal and market presence in the Golden State. Their headquarters span several vibrant locations, such as San Diego, South San Francisco, and Palo Alto, making California a key player in the biopharmaceutical landscape.

Read on to discover the top biopharmaceutical companies in California.

Top 22 Biopharmaceutical Companies Companies in California

1. Dendreon

• Website: dendreon.com
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, based in Seal Beach, California, is a biotechnology company that specializes in immunotherapy for cancer treatment. Founded in 1992, Dendreon has made significant strides in the biopharmaceutical industry with its flagship product, Provenge (sipuleucel-T), which is an FDA-approved treatment for advanced prostate cancer. This innovative therapy harnesses the power of the patient's own immune cells to detect and attack cancer cells, marking a significant advancement in personalized medicine. Since its approval in 2010, Provenge has been prescribed to nearly 40,000 men, demonstrating its impact on patient survival rates. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, aiding other companies in the development and commercialization of novel cancer therapies. With a workforce of approximately 610 employees, Dendreon continues to invest in research and clinical trials to expand the applications of Provenge and enhance treatment options for prostate cancer patients.

2. Aimmune Therapeutics

• Website: aimmune.com
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 81%, United Kingdom (UK) 10%, Switzerland 5%, Other 4%
• Latest funding: $2.6B, August 2020
• Founded year: 2011
• Headcount: 501-1000
• LinkedIn: aimmune-therapeutics

Aimmune Therapeutics, based in Brisbane, California, is a biopharmaceutical company dedicated to developing innovative therapies for food allergies and related gastrointestinal and metabolic diseases. Founded in 2011, Aimmune aims to transform the lives of patients and their families by providing effective treatments that improve quality of life. The company collaborates with prominent biotechnology firms to enhance its research and development efforts. Aimmune's focus on food allergies is particularly significant, as these conditions are on the rise, impacting a substantial portion of the population. In 2020, Aimmune secured $2.6 billion in funding, reflecting strong market confidence in its mission and potential. As a subsidiary of Nestlé Health Science, Aimmune benefits from additional resources and expertise, further solidifying its position in the biopharmaceutical industry.

3. Calico Life Sciences

• Website: calicolabs.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Latest funding: Seed, January 2021
• Founded year: 2013
• Headcount: 201-500
• LinkedIn: calico-life-sciences-llc

Calico Life Sciences LLC, founded in 2013 and based in South San Francisco, California, is a biotechnology company dedicated to research and development in the field of aging and age-related diseases. The company aims to harness advanced technologies to deepen the understanding of aging biology and to create novel therapies that can improve healthspan. With a workforce of approximately 384 employees, Calico operates primarily in the United States. They are not a traditional biopharmaceutical entity; instead, they blend aspects of both biotechnology and academic research to explore complex questions about aging. Their clinical trials include studies on conditions such as Vanishing White Matter Disease and Amyotrophic Lateral Sclerosis, showcasing their commitment to translating research into potential treatments. Calico's partnership with AbbVie provides them with additional resources and expertise, further strengthening their drug development pipeline. Their focus on innovative science and collaboration positions them as a noteworthy player in the biopharmaceutical sector.

4. Vividion Therapeutics, Inc.

• Website: vividion.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.5B, August 2021
• Founded year: 2017
• Headcount: 201-500
• LinkedIn: vividion-therapeutics

Vividion Therapeutics, Inc., founded in 2017 and based in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for cancer and immune disorders. The company specializes in creating selective small molecules that target proteins previously deemed undruggable. Vividion employs a proprietary chemoproteomic platform to identify novel binding sites on proteins, enabling the development of innovative therapies. Their pipeline includes programs targeting key proteins such as NRF2, STAT3, and WRN, which are critical in oncology and immunology. Vividion has attracted substantial funding, with a reported last funding amount of $1.5 billion in August 2021, underscoring its potential in the biopharmaceutical industry. The company is actively expanding its research and development capabilities, further solidifying its position in the market.

5. Dermavant Sciences, an Organon company

• Website: dermavant.com
• Ownership type: Corporate
• Headquarters: Long Beach, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2024
• Founded year: 2016
• Headcount: 201-500
• LinkedIn: dermavant-sciences

Dermavant Sciences, a subsidiary of Organon, is a biopharmaceutical company based in Long Beach, California. Founded in 2016, Dermavant is dedicated to developing and commercializing innovative therapeutics in the field of immuno-dermatology. The company primarily focuses on addressing significant unmet medical needs in chronic skin conditions. Their flagship product, VTAMA cream (tapinarof), has been approved for the treatment of plaque psoriasis in adults and is currently undergoing further development for atopic dermatitis. Dermavant's clinical research efforts are aimed at providing effective, non-steroidal treatment options that enhance patient quality of life. The company is actively engaged in expanding its pipeline, which includes both late-stage and earlier development candidates targeting immunological and inflammatory diseases. Dermavant's commitment to scientific innovation and patient care underscores its role in the biopharmaceutical industry.

6. NantKwest

• Website: nantkwest.com
• Ownership type: Corporate
• Headquarters: Culver City, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2020
• Founded year: 2002
• Headcount: 51-200
• LinkedIn: nantkwest

NantKwest, now operating under the name ImmunityBio, is a biotechnology company based in Culver City, California. Founded in 2002, the company specializes in developing innovative immunotherapies aimed at treating cancer and infectious diseases. Their flagship product, ANKTIVA®, has gained attention for its role in activating the body's immune system to combat tumors. ImmunityBio is currently involved in numerous clinical trials, with a robust pipeline that includes therapies for various cancers such as bladder cancer, glioblastoma, and non-small cell lung cancer. The company collaborates with research institutions, including the National Cancer Institute, to explore new avenues for cancer prevention and treatment. Their commitment to enhancing patient outcomes through personalized immunotherapy reflects a significant focus on addressing unmet medical needs in oncology and infectious diseases.

7. TrueBinding

• Website: truebinding.com
• Ownership type: Venture Capital
• Headquarters: Foster City, California, United States (USA)
• Latest funding: $57.7M, July 2023
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: immutics

TrueBinding Inc., founded in 2016 and based in Foster City, California, is a clinical-stage biotherapeutic company dedicated to creating innovative monoclonal antibody therapeutics. The company specializes in addressing neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as other medical conditions with significant unmet needs. TrueBinding's proprietary platform technology has enabled them to discover and validate multiple novel drug targets, showcasing their potential in drug development. They are currently conducting clinical trials, including an Expanded Access Program for their investigational drug TB006, which aims to provide treatment options for patients with Alzheimer's disease. TrueBinding has also received substantial funding, with their latest round totaling over $57 million in July 2023, reflecting strong investor confidence in their mission and capabilities. In addition to their therapeutic development efforts, TrueBinding offers contract development and manufacturing services, further solidifying their role in the biopharmaceutical industry.

8. Mapp Biopharmaceutical Inc

• Website: mappbio.com
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $16.5M, June 2019
• Founded year: 2003
• Headcount: 51-200
• LinkedIn: mapp-biopharmaceutical-inc

Mapp Biopharmaceutical Inc, founded in 2003, is a biopharmaceutical company based in San Diego, California. The firm specializes in developing novel therapeutics for the prevention and treatment of infectious diseases, with a particular emphasis on unmet needs in global health and biodefense. Mapp collaborates with various government agencies and healthcare organizations to tackle critical health challenges. Their product offerings include monoclonal antibody therapies designed to combat serious viral threats. Notably, the company has received funding, including a $16.5 million grant in June 2019, which underscores its ongoing commitment to advancing its therapeutic developments. Mapp's recent initiatives, such as human trials for a monoclonal antibody targeting the Nipah virus and partnerships with BARDA for Marburg virus therapeutics, further illustrate its active role in the biopharmaceutical sector.

9. 858 Therapeutics

• Website: 8five8tx.com
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: 858-therapeutics

858 Therapeutics is a biotechnology company based in San Diego, California, founded in 2019. The company specializes in drug discovery and development, focusing on oncology and immunology. They are dedicated to creating small molecule therapeutics that target novel therapeutic pathways. Their lead program involves a PARG inhibitor, which is currently in early clinical development. This inhibitor is designed to disrupt cancer cell survival mechanisms, particularly in solid tumors. The company operates in a competitive sector, aiming to provide innovative solutions for patients facing cancer and immune diseases. With a team of experienced professionals from the pharmaceutical and biotech industries, 858 Therapeutics is positioned to make significant contributions to the biopharmaceutical landscape.

10. Star Therapeutics

• Website: star-therapeutics.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $90.0M, September 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: star-tx

Star Therapeutics, based in South San Francisco, California, is a biotechnology firm dedicated to developing innovative antibody therapies aimed at serious diseases. Founded in 2018, the company has made significant strides in its research and development efforts, focusing on addressing unmet medical needs. Their approach is characterized by a pipeline-in-a-product strategy, which allows them to create best-in-class therapeutics based on novel biological insights. Star Therapeutics has recently gained attention for its clinical programs, particularly in the area of bleeding disorders, with a focus on von Willebrand disease. The company has successfully raised $90 million in a Series C funding round in September 2023, which will help accelerate its pipeline and support the growth of its portfolio companies. This funding reflects the confidence investors have in Star Therapeutics' potential to transform patient lives through effective treatment options.

11. Cartography Biosciences

• Website: cartography.bio
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $57.0M, July 2022
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: cartographybio

Cartography Biosciences is a biotechnology firm based in South San Francisco, California, founded in 2020. The company specializes in the development of cancer immunotherapies, focusing on identifying precise targets for treatment. By utilizing advanced technologies such as single-cell genomics and proteomics, Cartography aims to enhance the effectiveness and safety of cancer therapies. Their innovative approach includes creating a comprehensive antigen atlas to analyze cancer through antigen expression, which could lead to more effective treatments for various cancers. The company has attracted significant investment, securing $57 million in Series A funding in July 2022, which supports their ongoing research and development initiatives. Cartography's primary customers include healthcare providers and pharmaceutical companies seeking cutting-edge solutions in oncology.

12. Eidos Therapeutics

• Website: eidostx.com
• Ownership type: Corporate
• Headquarters: San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $175.0M, October 2020
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: eidos-therapeutics

Eidos Therapeutics, based in San Francisco, California, is a biotechnology company founded in 2016. It operates under the umbrella of BridgeBio Pharma and is dedicated to developing transformative medicines for genetic diseases. The company is particularly focused on transthyretin amyloidosis (ATTR), a rare and life-threatening condition that can severely impact the heart and nervous system. Eidos is advancing investigational therapies like Acoramidis, which aims to stabilize the transthyretin protein and improve patient outcomes. The company has garnered significant funding, with a reported amount of $175 million in its last funding round in October 2020. This financial backing supports its mission to bring effective treatments to patients suffering from rare genetic disorders, highlighting its relevance in the biopharmaceutical industry.

13. GigaGen Inc

• Website: gigagen.com
• Ownership type: Corporate
• Headquarters: San Carlos, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $80.0M, March 2021
• Founded year: 2010
• Headcount: 11-50
• LinkedIn: gigagen-inc

GigaGen Inc, based in San Carlos, California, is a biopharmaceutical company founded in 2010. The company is dedicated to the discovery and development of innovative antibody drugs, focusing on recombinant polyclonal and monoclonal antibodies aimed at treating immunodeficiencies, infectious diseases, and various cancers. GigaGen employs advanced technologies to enhance drug discovery processes, which has led to the development of their first recombinant polyclonal antibody drugs. Their pipeline includes promising candidates like GIGA-564, a monoclonal antibody targeting CTLA-4, currently undergoing Phase 1 trials. GigaGen's commitment to innovation is underscored by their receipt of $80 million in funding in March 2021, which supports their ongoing research and development efforts. The company collaborates with healthcare providers and pharmaceutical companies, positioning itself as a key player in the biopharmaceutical industry.

14. pH Pharma Inc.

• Website: ph-pharma.com
• Ownership type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Latest funding: January 2018
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: ph-pharma-co.-ltd.

pH Pharma Inc., based in Palo Alto, California, is a biotechnology firm founded in 2015. The company is dedicated to developing innovative healthcare products aimed at addressing unmet clinical needs. Specializing in drug development for conditions such as glaucoma and non-alcoholic steatohepatitis (NASH), pH Pharma operates both research and manufacturing facilities. Their pipeline includes promising candidates like Sovesudil, which is currently in clinical trials for glaucoma treatment. The company actively collaborates with a global network of partners to enhance its research capabilities and expedite the development of effective treatments. With a team of professionals experienced in the biopharmaceutical industry, pH Pharma is positioned to make significant contributions to healthcare.

15. Eikon Therapeutics

• Website: eikontx.com
• Ownership type: Private Equity
• Headquarters: Hayward, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $350.7M, February 2025
• Founded year: 2019
• Headcount: 201-500
• LinkedIn: eikon-therapeutics-inc

Eikon Therapeutics, founded in 2019 and based in Hayward, California, is a biotechnology firm dedicated to advancing innovative therapeutics. The company specializes in drug discovery and development, focusing on critical areas such as oncology, immunology, and neuroscience. Eikon employs proprietary technologies, including Single Molecule Tracking, to gain insights into protein dynamics, which is essential for developing new therapies. Their pipeline includes clinical programs that have shown promise in treating solid tumors, alongside numerous preclinical initiatives. Eikon has attracted significant investment, with a recent Series D funding round raising approximately $350.7 million, underscoring investor confidence in their mission to address serious diseases with unmet medical needs.

16. Pipeline Therapeutics

• Website: pipelinetherapeutics.com
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Latest funding: Series C, $80.0M, February 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: pipelinetherapeutics.com

Pipeline Therapeutics, founded in 2017 and based in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel oral small molecule therapies. The company focuses on neuroscience, inflammation, and immunology, targeting specific biological pathways associated with clinical disabilities. Their lead products, PIPE-791 and PIPE-307, are currently in clinical trials, with PIPE-791 undergoing Phase 1 trials for idiopathic pulmonary fibrosis and progressive multiple sclerosis, while PIPE-307 is in Phase 2 trials for relapse-remitting multiple sclerosis and depression. Pipeline Therapeutics has attracted significant investment, raising $80 million in a Series C funding round in February 2021, which underscores their potential in the biopharmaceutical sector. Their collaboration with Johnson & Johnson for PIPE-307 further highlights their strategic partnerships in advancing therapeutic development.

17. Inmagene Biopharmaceuticals

• Website: inmagenebio.com
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: China 88%, United States (USA) 12%
• Latest funding: Series C, $100.0M, June 2021
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: inmagene-biopharmaceuticals

Inmagene Biopharmaceuticals, based in San Diego, California, is a biopharmaceutical company that specializes in developing innovative therapies aimed at treating immunological and inflammatory diseases. Founded in 2019, the company leverages its proprietary QuadraTek® platform to create drug candidates that are designed to meet significant medical needs. Inmagene's pipeline includes several promising candidates, such as IMG-007, which targets atopic dermatitis and alopecia areata, and IMG-004, a small molecule aimed at rheumatoid arthritis and chronic spontaneous urticaria. The company has established strategic partnerships to enhance its development capabilities and has successfully raised $100 million in funding as of June 2021. This financial backing supports their ongoing clinical trials and research efforts, positioning Inmagene as a noteworthy entity in the biopharmaceutical sector.

18. EpicentRx, Inc.

• Website: epicentrx.com
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $500,000, July 2022
• Founded year: 2002
• Headcount: 11-50
• LinkedIn: epicentrx

EpicentRx, Inc. is a biotechnology firm based in San Diego, California, established in 2002. The company is dedicated to developing novel therapies aimed at treating inflammatory diseases and cancer. Their product pipeline includes Nibrozetone (RRx-001), which is currently in Phase 3 trials, and AdAPT (AdAPT-001), an immune checkpoint-stimulating anticancer immunotherapy. EpicentRx operates with a small team of 11-50 employees, emphasizing a focused and specialized approach to their research. The company has received funding, including a grant of $500,000 in July 2022, which supports their ongoing projects and clinical trials. Their commitment to addressing significant medical needs positions them as a relevant entity in the biopharmaceutical industry.

19. BlossomHill Therapeutics, Inc.

• Website: bhtherapeutics.com
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $100.0M, January 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: blossomhill-therapeutics-inc

BlossomHill Therapeutics, Inc. is a biotechnology firm based in San Diego, California, founded in 2020. The company is dedicated to developing precision medicines aimed at treating oncology and autoimmune diseases. With a team that boasts a strong track record in FDA-approved therapies, BlossomHill is focused on creating innovative solutions that address the challenges of treatment resistance. Their pipeline includes promising candidates like BH-30236 and BH-30643, which are currently in clinical trials. The company has successfully raised $100 million in Series B funding as of January 2024, underscoring investor confidence in their mission to redefine treatment standards. BlossomHill's leadership, particularly that of CEO Dr. J. Jean Cui, is notable for its experience in drug design, having previously contributed to the development of several market-approved cancer therapies. This combination of expertise and ambition positions BlossomHill as a noteworthy player in the biopharmaceutical industry.

20. HUYABIO International

• Website: huyabio.com
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 72%, China 15%, Japan 6%, Other 8%
• Latest funding: Other (Debt), $48.0M, April 2015
• Founded year: 2004
• Headcount: 51-200
• LinkedIn: huya-bioscience-international

HUYABIO International, founded in 2004 and based in San Diego, California, is a private biopharmaceutical company dedicated to globalizing China's pharmaceutical innovations. The company specializes in developing novel therapeutic compounds, with a strong emphasis on oncology and cardiovascular health. HUYABIO collaborates with research institutions and pharmaceutical companies to identify and license promising pre-clinical and clinical stage compounds from China. This approach not only accelerates the development process but also lowers the associated risks. HUYABIO's pipeline includes several noteworthy programs, such as HBI-8000, a novel epigenetic drug for cancer treatment, and HBI-3000, aimed at treating atrial fibrillation. The company has received funding amounting to $48 million, which supports its ongoing research and development efforts. With a workforce of around 109 employees and a presence in multiple countries, HUYABIO is positioned to make significant contributions to the global biopharmaceutical market.

21. Hexagon Bio

• Website: hexagonbio.com
• Ownership type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $77.3M, October 2022
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: hexagon-bio

Hexagon Bio, founded in 2016 and based in Menlo Park, California, is a biotechnology firm dedicated to the discovery and development of new drugs, with a strong emphasis on cancer therapies. The company utilizes advanced technologies in genomics and synthetic biology to mine microbial genomes for novel compounds that can be transformed into effective treatments. Their focus on antibody drug conjugates positions them at the forefront of cancer therapeutics, addressing significant unmet medical needs. Hexagon Bio has attracted substantial investment, including a recent Series B funding round of $77.3 million in October 2022, which underscores their potential in the biopharmaceutical sector. Their team comprises experts from various scientific disciplines, all working towards the common goal of revolutionizing cancer treatment through innovative drug discovery.

22. Askgene Pharma, INC.

• Website: ask-gene.com
• Ownership type: Venture Capital
• Headquarters: Camarillo, California, United States (USA)
• Latest funding: Series A, July 2023
• Founded year: 2012
• Headcount: 1-10
• LinkedIn: askgene-pharma-inc.

AskGene Pharma, INC., founded in 2012 and based in Camarillo, California, is a biotechnology firm dedicated to the development of innovative cytokine prodrugs and immunotherapies. The company specializes in addressing unmet medical needs in oncology and autoimmune diseases through its proprietary SmartKine platform, which significantly improves the pharmacokinetics and safety profiles of cytokines. AskGene Pharma collaborates with healthcare providers and research institutions to provide advanced therapeutic options. Recently, they have made headlines by initiating a Phase 3 pivotal trial for ASKB589, a monoclonal antibody targeting CLDN18.2, aimed at treating advanced gastric and gastroesophageal junction cancers. This trial marks a critical step in their pipeline, showcasing their commitment to advancing cancer therapies. With a small team of experienced scientists, AskGene Pharma is focused on bringing next-generation therapies to market, contributing to the evolving landscape of biopharmaceuticals.

Biopharmaceutical Companies Insights: Key Companies in California

Company	Headquarter	Size	Founded	Ownership
Dendreon	Seal Beach, California, United States (USA)	501-1000	1992	Corporate
Aimmune Therapeutics	Brisbane, California, United States (USA)	501-1000	2011	Corporate
Calico Life Sciences	South San Francisco, California, United States (USA)	201-500	2013	Venture Capital
Vividion Therapeutics, Inc.	San Diego, California, United States (USA)	201-500	2017	Corporate
Dermavant Sciences, an Organon company	Long Beach, California, United States (USA)	201-500	2016	Corporate
NantKwest	Culver City, California, United States (USA)	51-200	2002	Corporate
TrueBinding	Foster City, California, United States (USA)	51-200	2016	Venture Capital
Mapp Biopharmaceutical Inc	San Diego, California, United States (USA)	51-200	2003	Private
858 Therapeutics	San Diego, California, United States (USA)	11-50	2019	Private
Star Therapeutics	South San Francisco, California, United States (USA)	11-50	2018	Venture Capital
Cartography Biosciences	South San Francisco, California, United States (USA)	11-50	2020	Venture Capital
Eidos Therapeutics	San Francisco, California, United States (USA)	11-50	2016	Corporate
GigaGen Inc	San Carlos, California, United States (USA)	11-50	2010	Corporate
pH Pharma Inc.	Palo Alto, California, United States (USA)	11-50	2015	Venture Capital
Eikon Therapeutics	Hayward, California, United States (USA)	201-500	2019	Private Equity
Pipeline Therapeutics	San Diego, California, United States (USA)	11-50	2017	Venture Capital
Inmagene Biopharmaceuticals	San Diego, California, United States (USA)	11-50	2019	Venture Capital
EpicentRx, Inc.	San Diego, California, United States (USA)	11-50	2002	Venture Capital
BlossomHill Therapeutics, Inc.	San Diego, California, United States (USA)	11-50	2020	Venture Capital
HUYABIO International	San Diego, California, United States (USA)	51-200	2004	Private
Hexagon Bio	Menlo Park, California, United States (USA)	51-200	2016	Venture Capital
Askgene Pharma, INC.	Camarillo, California, United States (USA)	1-10	2012	Venture Capital

Want to Find More Biopharmaceutical Companies Companies?

If you want to find more companies that ...provide groundbreaking therapies and advanced medical solutions you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!